Key facts
- This page summarizes Christopher Rovaldi's Form 4 filing for Keros Therapeutics, Inc. (KROS).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 03 Feb 2022, 15:45.
Christopher Rovaldi - 01 Feb 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)
- Signature
- /s/ Esther Cho, Attorney-in-Fact
- Issuer symbol
- KROS
- Transactions as of
- 01 Feb 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 03 Feb 2022, 15:45:42 UTC
- Next filing
- 05 Apr 2022
- SEC
- View on sec.gov
Key filing fact
Christopher Rovaldi filed Form 4 for Keros Therapeutics, Inc. (KROS) on 03 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
KROS
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $49.34
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | One-fourth (1/4th) of the shares subject to the option shall vest on February 1, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |